• Inside Arbor’s CNS pipeline and next-generation gene editing
    13 Nov 2026

    Gene editing has spent the last decade proving what's possible in the lab. The next decade is about proving it can reach the patients who need it most, from ultra-rare liver diseases to conditions like ALS, where no truly effective treatments exist today.

    Arbor Biotechnologies is one of the companies pushing that frontier, built on a diverse toolbox of editing technologies that goes beyond the limitations of first-generation CRISPR tools. Its lead clinical program, ABO-101, targets PH1, and last October the company struck a partnership with Chiesi Group worth up to two billion dollars in milestones, with European regulators granting the program orphan drug designation just this summer.

    Arbor is also building out a CNS pipeline focused initially on ALS. Here to talk through the science, the strategy, and what's next is Devyn Smith, CEO of Arbor Biotechnologies.

    01:36 – Meet Devyn Smith

    07:48 – Arbor's toolbox approach versus single-editor CRISPR companies

    12:16 – What PH1 is and how ABO-101 works

    15:19 – Inside the Chiesi partnership for ABO-101

    20:14 – Why ALS anchors Arbor's CNS pipeline

    26:48 – Arbor's three-year outlook and long-term vision

    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

    Stay updated by subscribing to our newsletter

    To dive deeper into the topic:

    • What’s on the horizon for gene editing-based therapies?
    • CRISPR technology’s next wave: Ten companies to watch in 2025
    • Beyond CRISPR: What CAST could bring to genome editing
    Toon meer Toon minder
    32 min.
  • How to turn a BIO-Europe meeting into a lasting partnership
    6 Nov 2026

    Partnering season is here. As the biopharma community heads to BIO-Europe and the busy end-of-year conference calendar, the question isn’t just who you meet, but how you make those meetings count. In this special episode of Beyond Biotech, we’re talking about the small details that make a big difference at global conferences.

    Joining me is Shashi Koduru, Senior Director of Business Development at Vector BioMed. Shashi shares how he plans his on-site schedule, finds the right partners, and makes short meetings productive. We also talk about follow-up, sharing materials after the event, and turning a first conversation into a lasting partnership.

    • 01:15 Meet Shashi Koduru
    • 05:13 Vector BioMed’s mission for affordable lentiviral vectors
    • 09:36 Cutting through the noise with early conference prep
    • 19:04 Making the most of a 30-minute partnering meeting
    • 22:46 How a chance BIO encounter became a client
    • 25:24 Following up and maintaining momentum after the event

    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

    Stay updated by subscribing to our newsletter

    To dive deeper into the topic:

    • Episode 188: How to optimize your biotech company for partnering, licensing, and business success
    • The ABC of biotech partnerships
    • Nine tips to succeed in pharma-biotech partnerships
    Toon meer Toon minder
    32 min.
  • Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)
    30 Oct 2026

    Welcome to a special three-part series called 'The Metabolic Moment'.

    In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure.

    So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment.

    In part three of our series and ahead of Diabetes Awareness Month, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes, the realities of making gene therapies at scale, and where a potential one-time treatment could fit alongside GLP-1s.

    • 02:21 Meet Ryan Confer and Genprex
    • 09:49 What gene therapy can offer patients that GLP-1s cannot
    • 12:36 How GPX-002 works and the type 2 diabetes data presented at ASGCT
    • 17:22 Working with a CDMO to manufacture an AAV gene therapy at scale
    • 20:07 Standing out from GLP-1s and stem cell approaches in diabetes
    • 27:59 Diabetes Awareness Month and the prospect of a functional cure

    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

    Stay updated by subscribing to our newsletter

    To dive deeper into the topic:

    • The Metabolic Moment: 3 big bets to watch in metabolic disease
    • Beyond GLP-1s: is there a new wave of metabolic disease treatments?
    • The future of diabetes treatment: Is a cure possible?
    Toon meer Toon minder
    35 min.
  • GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)
    23 Oct 2026

    Welcome to a special three-part series called 'The Metabolic Moment'.

    In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure.

    So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment.

    In part two of our series, I’m joined by Paul Little, CEO of Atrogi. We talk about what GLP-1s leave unsolved, the science behind ATR-258, and how a small company competes in a market led by giants.

    • 02:24 Meet Paul Little
    • 05:08 What GLP-1s leave unsolved, from muscle loss to weight rebound
    • 10:29 How ATR-258 tunes beta-2 signalling to mimic exercise
    • 16:11 Avoiding the cardiovascular side effects of older beta-2 agonists
    • 19:03 What the new muscle power and body composition data mean
    • 22:03 Phase 2 options, oral advantages and the path to partnering

    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

    Stay updated by subscribing to our newsletter

    To dive deeper into the topic:

    • The Metabolic Moment: 3 big bets to watch in metabolic disease
    • Beyond Ozempic: the GLP-1 landscape in 2026
    • What can GLP-1s do beside treat diabetes and obesity?
    Toon meer Toon minder
    28 min.
  • The next big shake-up in the GLP-1 market? (Part 1 of 3)
    16 Oct 2026

    Welcome to a special three-part series called 'The Metabolic Moment'.

    In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure.

    So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment.

    In part one of our series, I’m joined by Valeriia Simanovskaia, founder and CEO of BioBrokers, an independent capital markets and strategic advisory firm for life sciences. Trained at Harvard Medical School and based in Paris, Valeriia tracks where the money in biotech is flowing.

    • 02:15 Meet Valeriia and BioBrokers
    • 09:07 Discontinuation rates and what they mean for GLP-1 sales
    • 12:39 Generic semaglutide arrives in India and Canada
    • 16:28 Why oral GLP-1s may become a separate market segment
    • 22:15 Amgen’s MariTide and the case for monthly dosing
    • 32:00 Why weight maintenance is the next competitive frontier

    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

    Stay updated by subscribing to our newsletter

    To dive deeper into the topic:

    • The Metabolic Moment: 3 big bets to watch in metabolic disease
    • Beyond Ozempic: the GLP-1 landscape in 2026
    • Nine biotech companies that could revolutionize obesity treatments
    Toon meer Toon minder
    36 min.
  • Saudi Arabia's biotech momentum: inside RGMBS 2026
    9 Oct 2026

    Saudi Arabia has spent the last four years building one of the most ambitious biotech gatherings in the region: the Riyadh Global Medical Biotechnology Summit. This September, the fourth edition brought together delegations from more than 57 countries and over 200 speakers, closing with more than 40 agreements and initiatives worth over SAR5 billion. From gene editing and genomics to AI-driven drug discovery and biomanufacturing, the Summit is positioning itself as a serious node in the global biotech map — and it's timed deliberately, arriving just weeks before BIO-Europe in Cologne.

    To unpack what happened in Riyadh, what it means for Saudi Arabia's biotech ambitions, and how the Summit connects to the conversations happening at BIO-Europe, I'm joined by Abdulaziz Aldayel, a nanomedicine researcher at the King Abdullah International Medical Research Center.

    • 01:20 – Meet Abdulaziz Aldayel
    • 07:21 – What RGMBS has set out to achieve since 2021
    • 11:44 – RGMBS dealmaking jumps to $1.3 billion
    • 21:17 – How RGMBS and BIO-Europe complement each other
    • 28:14 – What to expect at the next RGMBS

    This episode is presented with the support of RGMBS. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

    Stay updated by subscribing to our newsletter

    To dive deeper into the topic:

    • Genomes to bioreactors: Saudi Arabia’s gene editing oncology push
    • Saudi Arabia: is the country set to become a global biotech hub?
    • Saudi Arabia to inject $3B into vaccines and medicines industry
    Toon meer Toon minder
    34 min.
  • How Flagship's Valo is reshaping AI drug discovery with human data
    2 Oct 2026

    AI has been one of the biggest buzzwords in biotech for years now — but for all the technological progress, actual R&D productivity gains have been hard to find, and the cost of developing a new drug keeps climbing. My guest today believes that's because AI alone was never going to be the answer.

    Valo, a biotech founded by Flagship Pioneering, is betting on a different approach: combining AI, predictive chemistry, and — crucially — real-world human data from the very start of drug discovery, using access to more than 17 million longitudinal patient records, some spanning 20 years. That approach has already attracted major partners, including a Parkinson's collaboration with EMD Serono worth up to $3 billion and a cardiometabolic disease partnership with Novo.

    Joining me to talk about it is Valo's CEO, Brian Alexander — a former practicing radiation oncologist whose years treating patients with aggressive brain tumors helped shape his mission to reimagine how we discover medicines. Brian, welcome to the show.

    • 01:30 — Meet Brian Alexander
    • 04:17 — How treating brain tumor patients shaped his mission
    • 09:58 — Valo's two-platform approach to drug discovery
    • 16:23 — What 20-year patient records reveal about disease
    • 22:23 — Why Valo positions itself as pharma's R&D engine
    • 32:43 — How this approach could raise clinical success rates

    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

    Stay updated by subscribing to our newsletter

    To dive deeper into the topic:

    • Episode 198: The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data
    • How human-first datasets are reshaping AI drug discovery
    • Webinar: How AI has changed drug discovery & development, and what’s coming next
    Toon meer Toon minder
    36 min.
  • Theialife’s race to bring a childhood myopia treatment to market
    25 Sep 2026

    By 2050, nearly half the world's population is expected to be myopic, with around a billion people projected to progress to high myopia — a leading cause of irreversible vision loss later in life. Children face a narrow window in which to intervene, while the eye is still growing, before those structural changes become permanent. Yet despite the scale of the problem, there is still no FDA-approved drug that slows myopia progression in children, a gap underscored just last month when the FDA declined to approve an atropine eye drop for the same use.

    My guest today is Thomas Ruggia, President and CEO of Theialife, a late-stage biotech developing an oral therapy for pediatric myopia derived from a natural caffeine metabolite. Tom joins Theialife after 25 years in ophthalmology leadership, including roles at Johnson & Johnson, Alcon, Novartis, and most recently as CEO of Samsara Vision. We'll talk mechanism, evidence, and the road to Phase 3.

    01:49 Meet Thomas Ruggia

    06:50 How progressive myopia develops in children and why it's misunderstood

    15:55 ND10's mechanism of action

    19:51 20 years of Danish compassionate-use data vs. a randomised trial

    26:44 Why no FDA-approved pharmacologic therapy exists yet

    37:57 Theialife's pipeline beyond myopia

    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

    Stay updated by subscribing to our newsletter

    To dive deeper into the topic:

    • Innovation in ophthalmology: How biotechs are reshaping the treatment of eye diseases
    • Can gene therapy treat vision loss?
    • Europe’s Ophthalmology Scene Stays Hot for Biotech Funding
    Toon meer Toon minder
    44 min.